A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands. Issue 3 (23rd February 2021)

• Record Type: Journal Article
• Authors: Issa, Djamila E.; Dinmohamed, Avinash G.; Wondergem, Marielle J.; Blommestein, Hedwig M.; Huijgens, Peter C.; Lugtenburg, Pieternella J.; Visser, Otto; Zweegman, Sonja; Chamuleau, Martine E. D.
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 3(2021)
• Page Start: 549
• Page End: 559
• Publication Date: 2021-02-23
• Subjects: Diffuse large B-cell lymphoma -- R-CHOP -- population-based -- survival; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1842394
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Randomized controlled trials have studied different dose-intensity and dose-interval regimens of R-CHOP for patients with diffuse large B-cell lymphoma (DLBCL). This study was undertaken to confirm these results in a population-based setting, with special emphasis on the value of 6xR-CHOP21 among patients aged 18–64 years. Two thousand three hundred and thirty-eight stage II–IV DLBCL patients, ≥18 years, we confirmed the similar efficacy of six versus eight cycles of R-CHOP and of R-CHOP21 versus R-CHOP14 regimens across all age groups on overall survival (median follow-up 36.4 (1.3–167.6) months). Nevertheless, overall survival decreased with older age. Interestingly, in patients 18–64 years, the adjusted risk of mortality among recipients of 6xR-CHOP21 compared to other R-CHOP regimens seems to be similar (HR 0.62; 95%CI: 0.38–1.02; p = .059). Although this finding might suggest that 6xR-CHOP21 could be considered as first-line regimen for all stage II–IV DLBCL patients, it should be confirmed in forthcoming population-based studies with larger patient numbers and longitudinal follow-up.